|
 Gilead will combine its experimental drug lenacapavir, and Merck's
islatravir into a two-drug regimen that would allow for less
frequent, oral or injectable dosing for HIV patients.
Gilead and Merck will share global development and commercialization
costs 60% and 40%, respectively. The companies will have an equal
share in sales of the therapy until the revenue crosses certain
milestones.
The companies expect to begin testing in people an oral version of
the combination during the second half of this year.
[to top of second column] |
The news of the collaboration was first reported
by the Wall Street Journal.
(Reporting By Mrinalika Roy in Bengaluru;
Editing by Shounak Dasgupta)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
